Education
About Us
Working with TipRanks
Follow Us
Stereotaxis (STXS)
:STXS
Top Page
Stereotaxis
(NYSE MKT:STXS)
64Neutral
Positive Factors
Earnings
STXS posted 1Q revenue of $7.5M, beating the Street's $6.9M estimate by a comfortable margin.
Partnerships
STXS’s acceptance into the NVIDIA Connect program marks a pivotal milestone in its long-term innovation strategy, enabling future advanced AI integration to enhance robotic precision, automation, and decision support.
Product Innovation
GenesisX, Stereotaxis’ mobile robot that can be installed in days rather than months, has launched in Europe and is expected to be FDA cleared soon.
Negative Factors
Cash Flow
Free cash flow was positive in the quarter, at $1.3M, with no debt on the balance sheet.
Financial Performance
The 4Q operating loss was $7.6M, while the net loss was $7.5M.
Revenue Guidance
The company has a system backlog worth $15M, supporting the system revenue guidance for 2025.
Stereotaxis (STXS) vs. S&P 500 (SPY)
Market Cap
$178.02M
Dividend YieldN/A
Average Volume (3M)346.35K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth1.50%
EPS Growth-20.00%
CountryUS
Employees139
SectorHealthcare
Sector Strength41
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.07
Shares Outstanding86,000,850
10 Day Avg. Volume269,389
30 Day Avg. Volume346,350
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)27.85
Price to Sales (P/S)0.00
P/FCF Ratio-13.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.67Price Target Upside125.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Stereotaxis Business Overview & Revenue Model
Company DescriptionStereotaxis, Inc. (STXS) is a leading medical technology company specializing in the development and commercialization of advanced robotic systems for the treatment of cardiac arrhythmias. The company operates within the healthcare and medical devices sector, focusing on providing innovative solutions that enhance the precision and safety of minimally invasive surgery. Its core products include the Niobe Magnetic Navigation System and the Genesis RMN System, which facilitate remote-controlled, magnetic-guided catheter navigation, enabling electrophysiologists to perform complex cardiac procedures with improved accuracy and reduced risk.
How the Company Makes MoneyStereotaxis generates revenue primarily through the sale of its robotic navigation systems, related disposable interventional devices, and ongoing service contracts. A significant portion of its income is derived from the installation of its systems in hospitals and medical facilities, where it also earns revenue from the sale of consumables and accessories required for each procedure. The company also engages in partnerships with healthcare providers and institutions to expand its reach and enhance its product offerings. Service agreements, including maintenance and support for the installed systems, provide a recurring revenue stream, contributing to the company's financial stability.
Stereotaxis Financial Statement Overview
Summary
Stereotaxis demonstrates consistent revenue but struggles with profitability due to high operational costs, resulting in negative net income. The balance sheet shows balanced leverage with a debt-to-equity ratio of 0.99 but limited equity. Cash flow challenges persist, with negative free cash flow reflecting the need for improved cash management.Income Statement
Stereotaxis has shown marginal revenue growth over the years but faces challenges in profitability. The gross profit margin remains robust at around 54.2% for 2024, but the company continues to operate at a net loss, with a net profit margin of -94.2% in 2024. This indicates high operational costs relative to revenue, leading to negative EBIT and EBITDA margins, which suggest a need for cost management and strategic improvements.65
Positive
Balance Sheet
The debt-to-equity ratio for 2024 stands at approximately 0.99, showing a balanced leverage profile. However, the equity ratio is relatively low at 13.0%, indicating limited asset backing by equity. The company’s return on equity is negative due to sustained losses, highlighting potential financial stability concerns.60
Neutral
Cash Flow
Free cash flow has seen a slight improvement but remains negative, reflecting cash outflow challenges. The operating cash flow to net income ratio is unfavorable due to negative cash flows, indicating issues in converting revenue into cash. The free cash flow to net income ratio also highlights cash generation difficulties, requiring strategic cash flow management.58
Neutral
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 25.14M | 26.92M | 26.77M | 28.15M | 35.02M | 26.63M | Gross Profit |
| 14.12M | 14.59M | 14.86M | 18.47M | 23.23M | 18.97M | EBIT |
| -22.42M | -24.74M | -21.84M | -18.78M | -12.89M | -6.71M | EBITDA |
| -21.52M | -24.74M | -21.24M | -18.35M | -12.78M | -6.59M | Net Income Common Stockholders |
| -21.57M | -25.35M | -20.71M | -19.15M | -8.44M | -6.45M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 9.04M | 12.22M | 19.82M | 28.43M | 38.74M | 43.94M | Total Assets |
| 22.44M | 46.72M | 41.91M | 53.41M | 60.98M | 55.46M | Total Debt |
| 5.59M | 6.01M | 5.49M | 5.86M | 6.11M | 4.45M | Net Debt |
| -3.45M | -6.21M | -14.33M | -2.73M | -32.63M | -39.49M | Total Liabilities |
| 17.11M | 35.29M | 19.99M | 21.48M | 21.56M | 15.23M | Stockholders Equity |
| 5.33M | 6.08M | 21.92M | 31.93M | 39.42M | 40.23M |
| Cash Flow | Free Cash Flow | ||||
| -12.23M | -8.53M | -9.51M | -10.79M | -4.34M | -3.58M | Operating Cash Flow |
| -12.20M | -8.50M | -9.14M | -8.41M | -2.95M | -3.51M | Investing Cash Flow |
| 76.00K | 74.00K | 19.77M | -22.09M | -1.40M | -70.90K | Financing Cash Flow |
| 164.00K | 297.00K | 81.00K | 220.00K | 547.41K | 17.34M |
Stereotaxis Technical Analysis
Positive
2.07
Price Trends
1.90
Positive
2.07
Negative
2.06
Positive
Market Momentum
0.05
Positive
56.31
Neutral
53.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Positive. The current price of 2.07 is above the 20-day moving average (MA) of 2.03, above the 50-day MA of 1.90, and above the 200-day MA of 2.06, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 56.31 is Neutral, neither overbought nor oversold. The STOCH value of 53.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STXS.
Stereotaxis Risk Analysis
Stereotaxis disclosed 58 risk factors in its most recent earnings report. Stereotaxis reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stereotaxis Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $10.37B | 28.71 | 15.15% | 1.12% | 0.34% | 17.27% | |
70 Outperform | $5.84B | 48.47 | 9.16% | ― | 8.24% | 18.54% | |
66 Neutral | $12.66B | 23.98 | 11.77% | ― | 1.66% | 21.95% | |
65 Neutral | $1.62B | ― | -8.38% | ― | 15.79% | -1.20% | |
64 Neutral | $178.02M | ― | -179.82% | ― | 1.50% | -20.00% | |
52 Neutral | $5.15B | 3.02 | -44.64% | 2.83% | 16.44% | -0.47% | |
52 Neutral | $951.89M | 55.81 | -19.14% | ― | -14.44% | -557.38% |
* Healthcare Sector Average
Performance Comparison
STXS
Stereotaxis
2.07
-0.02
-0.96%
ATR
AptarGroup
157.01
10.12
6.89%
ATRC
Atricure
32.71
10.40
46.62%
HOLX
Hologic
56.79
-18.06
-24.13%
MMSI
Merit Medical Systems
98.83
15.77
18.99%
STAA
Staar Surgical
19.22
-23.58
-55.09%
Stereotaxis Earnings Call Summary
Earnings Call Date:May 12, 2025
(Q1-2025)
| % Change Since: 0.00%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted solid revenue growth and successful product launches, particularly in the European market. However, challenges persist with operating losses, uncertainties in the Chinese market, and temporary impacts on recurring revenue margins. Overall, the sentiment is neutral, balancing positive developments with existing challenges.Q1-2025 Updates
Positive Updates
Revenue Growth
The company reported a 9% year-over-year revenue growth for the first quarter, with total revenue reaching $7.5 million, up from $6.9 million in the prior year.
Map-iT Portfolio Success
The Map-iT family of EP catheters achieved sales over $1 million in the first quarter, with U.S. sales growing 30% sequentially from the fourth quarter.
MAGiC Catheter European Approval
The MAGiC ablation catheter received European approval, with initial adoption at approximately 20% of hospital customers.
GenesisX Launch
The company announced its first GenesisX purchase order and showcased the system at major electrophysiology conferences, receiving positive feedback.
Regulatory Progress
Significant progress on multiple fronts, including ongoing regulatory reviews of key technologies such as MAGiC in the U.S., GenesisX in the U.S., and MAGiC Sweep.
Revenue Guidance
The company reiterated its revenue guidance, expecting double-digit growth for the full year 2025 and recurring revenue reaching $7 million in the fourth quarter.
Negative Updates
Operating Loss
Operating loss for the first quarter was $5.9 million, compared with $4.7 million in the previous year.
Challenges in China
Uncertainty in the Chinese market due to macroeconomic conditions, affecting potential sales of Genesis systems.
System Revenue Decline
System revenue decreased from $2.6 million in the prior year first quarter to $2 million in the current quarter.
Recurring Revenue Margin Impact
Recurring revenue gross margins were impacted by acquisition-related accounting, temporarily reducing disposable margins.
Company Guidance
During the Stereotaxis First Quarter 2025 Earnings Call, the company reported a 9% year-over-year growth in revenue, totaling $7.5 million, with system revenue at $2 million and recurring revenue at $5.5 million. The Map-iT catheter sales exceeded $1 million, growing 30% sequentially in the U.S. The European launch of the MAGiC catheter is expected to generate approximately $1 million per quarter by year-end, while the GenesisX soft launch has begun, with the first order received in Q1. Gross margins stood at 54%, with recurring revenue margins impacted by acquisition-related accounting. Operating expenses were $10 million, including $3.2 million in non-cash charges. The company reiterated its guidance for double-digit revenue growth for the full year 2025, with an expected recurring revenue of $7 million in Q4. The anticipated U.S. regulatory approval for MAGiC is in the second half of the year, and GenesisX approval is expected in the summer.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.